Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Secondary Progressive Multiple SclerosisLu Z1,2, Zhao H1,2, Xu J3, Zhang Z1, Zhang X1, Zhang Y1, Liu Z1,2 and Xu Y1,2*
- Corresponding Author:
- Yun Xu, MD, PhD
Department of Neurology, Affiliated Drum Tower Hospital
Nanjing University Medical School, 321 Zhongshan Road
Nanjing, Jiangsu, 210008, P. R. China
Tel: +86 25 83105208
Fax: +86 25 83317016
E-mail: [email protected]
Received Date: October 25, 2013; Accepted Date: November 25, 2013; Published Date: November 27, 2013
Citation: Lu Z, Zhao H, Xu J, Zhang Z, Zhang X, et al. (2013) Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Secondary Progressive Multiple Sclerosis. J Stem Cell Res Ther S6:002. doi:10.4172/2157-7633.S6-002
Copyright: © 2013 Lu Z, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Background: Multiple sclerosis (MS) is an irreversible and demyelinating disease of the brain and spinal cord that causes significant disability in young people. However, therapeutic options to effectively stop the pathological progression of MS are limited. This study aimed to evaluate the safety and efficacy of human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) in the treatment of secondary progressive multiple sclerosis.
Methods: Eight patients with secondary progressive multiple scleroses were recruited from May 2010 and December 2010. Participants received intrathecal intravenous injections of hUC-MSCs. All patients were evaluated by Expanded Disability Status Scale, frequency of relapse, lymphocyte classification, magnetic resonance imaging (MRI) characteristics and adverse events from before treatment to up to 18 months after the infusion.
Results: The study suggested that, among the eight cases, six showed therapeutic improvement after hUCMSCs treatment and in all eight patients, relapse frequencies decreased to 36.4% of those before the treatment (1.2 ± 0.5 vs. 3.3 ± 0.7, p<0.05). Flow cytometry assay (FACS) indicated that blood T cells and B cells were inhibited after treatment. MRI characteristics also showed decreased volume and severity of lesions, with few adverse events. Conclusion: hUC-MSCs can alleviate disability and reduce relapse of secondary progressive multiple sclerosis by modulating immune responses, which also had been proved to be safe in MS patients. These findings suggest that transplantation of hUC-MSCs may be a potential therapy for MS.